Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis

All endpoints met Significant improvements in itch and quality of life Significant control of staph bacteria-associated and other AD flares Clearance of infected AD skin Significant improvements in inflammation ANNAPOLIS, Md., March 7, 2024 /PRNewswire/ — Alphyn, a clinical-stage…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.